Our Blog
See below for an opinion on current matters around the world.
It’s not easy being green: environmental sustainability in health systems, health industries and health economics
Have health and the PBS come of age as the Intergenerational Report turns 21?
The 2023 WHO Essential Medicines List & The Importance of Industry Engagement
The rise of India's pharmaceutical sector
What future from a ‘no-deal’ Brexit for UK life sciences?
New industrial policy for biopharmaceutical and devices industry needs careful thought
What trade war?: Western and Chinese life science companies just get on with it
Biopharmaceutical industry comes through in dealing with Ebola
History Repeats with the Release of the 2019 WHO Essential Medicines List
Australia's National Medicines Policy is outdated and in need of review
HTA 2.0: time for a reboot
UHC and medicine price transparency feature at 2019 World Health Assembly
Reflections on the art of political campaigning and advocacy
Alzheimer's failure a lesson in why pharma companies are vital
The WHO’s Essential Medicines List: Changing the Conversation
Universal health coverage and health technology assessment in Sub-Saharan Africa
Access Accelerated: NCDs and the pharmaceutical industry’s coming of age
Can we handle a cure?: the politics and economics of hepatitis C treatment
To price or not to price, that is the question
Don't forget the future: Alzheimer's disease and the economics of drug development